Skip to main content

Metabolic Imaging in Cardio-oncology

Journal of Cardiovascular Translational Research volume 13, pages 357–366 (2020)Cite this article

Abstract

Tremendous progress in cancer detection and therapy has improved survival. However, cardiovascular complications are a major source of morbidity in cancer survivors. Cardiotoxicity is currently defined by structural myocardial changes and cardiac injury biomarkers. In many instances, such changes are late and irreversible. Therefore, diagnostic modalities that can identify early alterations in potentially reversible biochemical and molecular signaling processes are of interest. This review is focused on emerging translational metabolic imaging modalities. We present in context relevant mitochondrial biology aspects that ground the development and application of these technologies for detection of cancer therapy–related cardiac dysfunction (CTRCD). The application of these modalities may improve the assessment of cardiovascular risk when anticancer treatments with a defined cardiometabolic toxic mechanism are to be used. Also, they may serve as screening tools for cardiotoxicity when novel lines of cancer therapies are applied.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig 1

References

  1. Plana, J. C., Galderisi, M., Barac, A., Ewer, M. S., Ky, B., Scherrer-Crosbie, M., Ganame, J., Sebag, I. A., Agler, D. A., Badano, L. P., Banchs, J., Cardinale, D., Carver, J., Cerqueira, M., JM, D. C., Edvardsen, T., Flamm, S. D., Force, T., Griffin, B. P., Jerusalem, G., Liu, J. E., Magalhaes, A., Marwick, T., Sanchez, L. Y., Sicari, R., Villarraga, H. R., & Lancellotti, P. (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr, 27, 911–939.

    PubMed  PubMed Central  Google Scholar 

  2. Jiji, R. S., Kramer, C. M., & Salerno, M. (2012). Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs. J Nucl Cardiol, 19, 377–388.

    PubMed  PubMed Central  Google Scholar 

  3. Neubauer, S. (2007). The failing heart--an engine out of fuel. N Engl J Med, 356, 1140–1151.

    PubMed  Google Scholar 

  4. Zhou, B., & Tian, R. (2018). Mitochondrial dysfunction in pathophysiology of heart failure. J Clin Invest, 128, 3716–3726.

    PubMed  PubMed Central  Google Scholar 

  5. Bertero, E., & Maack, C. (2018). Metabolic remodelling in heart failure. Nat Rev Cardiol, 15, 457–470.

    CAS  PubMed  Google Scholar 

  6. Varga, Z. V., Ferdinandy, P., Liaudet, L., & Pacher, P. (2015). Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol, 309, H1453–H1467.

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Doenst, T., Nguyen, T. D., & Abel, E. D. (2013). Cardiac metabolism in heart failure: implications beyond ATP production. Circ Res, 113, 709–724.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Tsutsui, H., Kinugawa, S., & Matsushima, S. (2011). Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol, 301, H2181–H2190.

    CAS  PubMed  Google Scholar 

  9. van der Pol, A., van Gilst, W. H., Voors, A. A., & van der Meer, P. (2019). Treating oxidative stress in heart failure: past, present and future. Eur J Heart Fail, 21, 425–435.

    PubMed  Google Scholar 

  10. Tahrir, F. G., Langford, D., Amini, S., Mohseni Ahooyi, T., & Khalili, K. (2019). Mitochondrial quality control in cardiac cells: mechanisms and role in cardiac cell injury and disease. J Cell Physiol, 234, 8122–8133.

    CAS  PubMed  Google Scholar 

  11. Goldenthal, M. J. (2016). Mitochondrial involvement in myocyte death and heart failure. Heart Fail Rev, 21, 137–155.

    CAS  PubMed  Google Scholar 

  12. Elmore, S. (2007). Apoptosis: a review of programmed cell death. Toxicol Pathol, 35, 495–516.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Zaha, V. G., Qi, D., Su, K. N., Palmeri, M., Lee, H. Y., Hu, X., Wu, X., Shulman, G. I., Rabinovitch, P. S., Russell 3rd, R. R., & Young, L. H. (2016). AMPK is critical for mitochondrial function during reperfusion after myocardial ischemia. J Mol Cell Cardiol, 91, 104–113.

    CAS  PubMed  Google Scholar 

  14. Renu K, V GA, P BT and Arunachalam S. Molecular mechanism of doxorubicin-induced cardiomyopathy - an update Eur J Pharmacol 2018;818:241-253.

  15. Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012). Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol, 52, 1213–1225.

    CAS  PubMed  Google Scholar 

  16. Xu, M. F., Tang, P. L., Qian, Z. M., & Ashraf, M. (2001). Effects by doxorubicin on the myocardium are mediated by oxygen free radicals. Life Sci, 68, 889–901.

    CAS  PubMed  Google Scholar 

  17. Zhang, S., Liu, X., Bawa-Khalfe, T., Lu, L. S., Lyu, Y. L., Liu, L. F., & Yeh, E. T. (2012). Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nat Med, 18, 1639–1642.

    PubMed  Google Scholar 

  18. Sterba, M., Popelova, O., Vavrova, A., Jirkovsky, E., Kovarikova, P., Gersl, V., & Simunek, T. (2013). Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal, 18, 899–929.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Ghigo, A., Li, M., & Hirsch, E. (1863). New signal transduction paradigms in anthracycline-induced cardiotoxicity. Biochim Biophys Acta, 2016, 1916–1925.

    Google Scholar 

  20. Jardines, L., Weiss, M., Fowble, B., & Greene, M. (1993). neu(c-erbB-2/HER2) and the epidermal growth factor receptor (EGFR) in breast cancer. Pathobiology., 61, 268–282.

    CAS  PubMed  Google Scholar 

  21. Force, T., Krause, D. S., & Van Etten, R. A. (2007). Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer, 7, 332–344.

    CAS  PubMed  Google Scholar 

  22. Moslehi, J. J. (2016). Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med, 375, 1457–1467.

    CAS  PubMed  Google Scholar 

  23. Feldman, A. M., Lorell, B. H., & Reis, S. E. (2000). Trastuzumab in the treatment of metastatic breast cancer: anticancer therapy versus cardiotoxicity. Circulation., 102, 272–274.

    CAS  PubMed  Google Scholar 

  24. Grazette, L. P., Boecker, W., Matsui, T., Semigran, M., Force, T. L., Hajjar, R. J., & Rosenzweig, A. (2004). Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol, 44, 2231–2238.

    CAS  PubMed  Google Scholar 

  25. ElZarrad, M. K., Mukhopadhyay, P., Mohan, N., Hao, E., Dokmanovic, M., Hirsch, D. S., Shen, Y., Pacher, P., & Wu, W. J. (2013). Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS One, 8, e79543.

    CAS  PubMed  PubMed Central  Google Scholar 

  26. Gordon, L. I., Burke, M. A., Singh, A. T., Prachand, S., Lieberman, E. D., Sun, L., Naik, T. J., Prasad, S. V., & Ardehali, H. (2009). Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem, 284, 2080–2087.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Deeks, E. D., & Keating, G. M. (2006). Sunitinib. Drugs., 66, 2255–2266 discussion 2267-8.

    CAS  PubMed  Google Scholar 

  28. Branca, M. A. (2005). Multi-kinase inhibitors create buzz at ASCO. Nat Biotechnol, 23, 639.

    CAS  PubMed  Google Scholar 

  29. Kerkela, R., Woulfe, K. C., Durand, J. B., Vagnozzi, R., Kramer, D., Chu, T. F., Beahm, C., Chen, M. H., & Force, T. (2009). Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-activated protein kinase. Clin Transl Sci, 2, 15–25.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. Manasanch, E. E., & Orlowski, R. Z. (2017). Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol, 14, 417–433.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Ross, J. M., Olson, L., & Coppotelli, G. (2015). Mitochondrial and ubiquitin proteasome system dysfunction in ageing and disease: two sides of the same coin? Int J Mol Sci, 16, 19458–19476.

    CAS  PubMed  PubMed Central  Google Scholar 

  32. Maharjan, S., Oku, M., Tsuda, M., Hoseki, J., & Sakai, Y. (2014). Mitochondrial impairment triggers cytosolic oxidative stress and cell death following proteasome inhibition. Sci Rep, 4, 5896.

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Fu, H. Y., Minamino, T., Tsukamoto, O., Sawada, T., Asai, M., Kato, H., Asano, Y., Fujita, M., Takashima, S., Hori, M., & Kitakaze, M. (2008). Overexpression of endoplasmic reticulum-resident chaperone attenuates cardiomyocyte death induced by proteasome inhibition. Cardiovasc Res, 79, 600–610.

    CAS  PubMed  Google Scholar 

  34. Abdurrachim, D., & Prompers, J. J. (1864). Evaluation of cardiac energetics by non-invasive (31)P magnetic resonance spectroscopy. Biochim Biophys Acta Mol basis Dis, 2018, 1939–1948.

    Google Scholar 

  35. Befroy, D. E., & Shulman, G. I. (2011). Magnetic resonance spectroscopy studies of human metabolism. Diabetes., 60, 1361–1369.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Qureshi, W. T., & Nasir, U. B. (2017). Principals and clinical applications of magnetic resonance cardiac spectroscopy in heart failure. Heart Fail Rev, 22, 491–499.

    PubMed  Google Scholar 

  37. Gabr, R. E., El-Sharkawy, A. M., Schar, M., Panjrath, G. S., Gerstenblith, G., Weiss, R. G., & Bottomley, P. A. (2018). Cardiac work is related to creatine kinase energy supply in human heart failure: a cardiovascular magnetic resonance spectroscopy study. J Cardiovasc Magn Reson, 20, 81.

    PubMed  PubMed Central  Google Scholar 

  38. Maslov, M. Y., Chacko, V. P., Stuber, M., Moens, A. L., Kass, D. A., Champion, H. C., & Weiss, R. G. (2007). Altered high-energy phosphate metabolism predicts contractile dysfunction and subsequent ventricular remodeling in pressure-overload hypertrophy mice. Am J Physiol Heart Circ Physiol, 292, H387–H391.

    CAS  PubMed  Google Scholar 

  39. Maslov, M. Y., Chacko, V. P., Hirsch, G. A., Akki, A., Leppo, M. K., Steenbergen, C., & Weiss, R. G. (2010). Reduced in vivo high-energy phosphates precede adriamycin-induced cardiac dysfunction. Am J Physiol Heart Circ Physiol, 299, H332–H337.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Gupta, A., Rohlfsen, C., Leppo, M. K., Chacko, V. P., Wang, Y., Steenbergen, C., & Weiss, R. G. (2013). Creatine kinase-overexpression improves myocardial energetics, contractile dysfunction and survival in murine doxorubicin cardiotoxicity. PLoS One, 8, e74675.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Landau, B. R., Spring-Robinson, C. L., Muzic Jr., R. F., Rachdaoui, N., Rubin, D., Berridge, M. S., Schumann, W. C., Chandramouli, V., Kern, T. S., & Ismail-Beigi, F. (2007). 6-Fluoro-6-deoxy-D-glucose as a tracer of glucose transport. Am J Physiol Endocrinol Metab, 293, E237–E245.

    CAS  PubMed  Google Scholar 

  42. Manabe, O., Kikuchi, T., Scholte, A., El Mahdiui, M., Nishii, R., Zhang, M. R., Suzuki, E., & Yoshinaga, K. (2018). Radiopharmaceutical tracers for cardiac imaging. J Nucl Cardiol, 25, 1204–1236.

    PubMed  Google Scholar 

  43. Bauckneht, M., Pastorino, F., Castellani, P., Cossu, V., Orengo, A. M., Piccioli, P., Emionite, L., Capitanio, S., Yosifov, N., Bruno, S., Lazzarini, E., Ponzoni, M., Ameri, P., Rubartelli, A., Ravera, S., Morbelli, S., Sambuceti, G., & Marini, C. (2019). Increased myocardial (18)F-FDG uptake as a marker of doxorubicin-induced oxidative stress. J Nucl Cardiol.

  44. Sarocchi, M., Bauckneht, M., Arboscello, E., Capitanio, S., Marini, C., Morbelli, S., Miglino, M., Congiu, A. G., Ghigliotti, G., Balbi, M., Brunelli, C., Sambuceti, G., Ameri, P., & Spallarossa, P. (2018). An increase in myocardial 18-fluorodeoxyglucose uptake is associated with left ventricular ejection fraction decline in Hodgkin lymphoma patients treated with anthracycline. J Transl Med, 16, 295.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Kim J, Cho SG, Kang SR, Yoo SW, Kwon SY, Min JJ, Bom HS and Song HC. Association between FDG uptake in the right ventricular myocardium and cancer therapy-induced cardiotoxicity. J Nucl Cardiol. 2019.

  46. O’Farrell, A. C., Evans, R., Silvola, J. M., Miller, I. S., Conroy, E., Hector, S., Cary, M., Murray, D. W., Jarzabek, M. A., Maratha, A., Alamanou, M., Udupi, G. M., Shiels, L., Pallaud, C., Saraste, A., Liljenback, H., Jauhiainen, M., Oikonen, V., Ducret, A., Cutler, P., McAuliffe, F. M., Rousseau, J. A., Lecomte, R., Gascon, S., Arany, Z., Ky, B., Force, T., Knuuti, J., Gallagher, W. M., Roivainen, A., & Byrne, A. T. (2017). A novel positron emission tomography (PET) approach to monitor cardiac metabolic pathway remodeling in response to sunitinib malate. PLoS One, 12, e0169964.

    PubMed  PubMed Central  Google Scholar 

  47. Taki, J., & Matsunari, I. (2007). Metabolic imaging using SPECT. Eur J Nucl Med Mol Imaging, 34(Suppl 1), S34–S48.

    CAS  PubMed  Google Scholar 

  48. DeGrado, T. R., Coenen, H. H., & Stocklin, G. (1991). 14(R,S)-[18F]fluoro-6-thia-heptadecanoic acid (FTHA): evaluation in mouse of a new probe of myocardial utilization of long chain fatty acids. J Nucl Med, 32, 1888–1896.

    CAS  PubMed  Google Scholar 

  49. Tadamura, E., Kudoh, T., Hattori, N., Inubushi, M., Magata, Y., Konishi, J., Matsumori, A., Nohara, R., Sasayama, S., Yoshibayashi, M., & Tamaki, N. (1998). Impairment of BMIPP uptake precedes abnormalities in oxygen and glucose metabolism in hypertrophic cardiomyopathy. J Nucl Med, 39, 390–396.

    CAS  PubMed  Google Scholar 

  50. Nishimura, T. (1999). beta-Methyl-p-(123I)-iodophenyl pentadecanoic acid single-photon emission computed tomography in cardiomyopathy. Int J Card Imaging, 15, 41–48.

    CAS  PubMed  Google Scholar 

  51. Saito, K., Takeda, K., Okamoto, S., Okamoto, R., Makino, K., Tameda, Y., Nomura, Y., Maeda, H., Ichihara, T., & Nakano, T. (2000). Detection of doxorubicin cardiotoxicity by using iodine-123 BMIPP early dynamic SPECT: quantitative evaluation of early abnormality of fatty acid metabolism with the Rutland method. J Nucl Cardiol, 7, 553–561.

    CAS  PubMed  Google Scholar 

  52. Naya, M., & Tamaki, N. (2014). Imaging of myocardial oxidative metabolism in heart failure. Curr Cardiovasc Imaging Rep, 7, 9244.

    PubMed  Google Scholar 

  53. Croteau, E., Gascon, S., Bentourkia, M., Langlois, R., Rousseau, J. A., Lecomte, R., & Benard, F. (2012). [11C]Acetate rest-stress protocol to assess myocardial perfusion and oxygen consumption reserve in a model of congestive heart failure in rats. Nucl Med Biol, 39, 287–294.

    CAS  PubMed  Google Scholar 

  54. Brown, M. A., Myears, D. W., & Bergmann, S. R. (1988). Noninvasive assessment of canine myocardial oxidative metabolism with carbon-11 acetate and positron emission tomography. J Am Coll Cardiol, 12, 1054–1063.

    CAS  PubMed  Google Scholar 

  55. Klein, L. J., Visser, F. C., Knaapen, P., Peters, J. H., Teule, G. J., Visser, C. A., & Lammertsma, A. A. (2001). Carbon-11 acetate as a tracer of myocardial oxygen consumption. Eur J Nucl Med, 28, 651–668.

    CAS  PubMed  Google Scholar 

  56. Nony, P., Guastalla, J. P., Rebattu, P., Landais, P., Lievre, M., Bontemps, L., Itti, R., Beaune, J., Andre-Fouet, X., & Janier, M. (2000). In vivo measurement of myocardial oxidative metabolism and blood flow does not show changes in cancer patients undergoing doxorubicin therapy. Cancer Chemother Pharmacol, 45, 375–380.

    CAS  PubMed  Google Scholar 

  57. Apps, A., Lau, J., Peterzan, M., Neubauer, S., Tyler, D., & Rider, O. (2018). Hyperpolarised magnetic resonance for in vivo real-time metabolic imaging. Heart., 104, 1484–1491.

    CAS  PubMed  PubMed Central  Google Scholar 

  58. Lauritzen, M. H., Sogaard, L. V., Madsen, P. L., & Ardenkjaer-Larsen, J. H. (2014). Hyperpolarized metabolic MR in the study of cardiac function and disease. Curr Pharm Des, 20, 6162–6170.

    CAS  PubMed  Google Scholar 

  59. Kurhanewicz, J., Vigneron, D. B., Ardenkjaer-Larsen, J. H., Bankson, J. A., Brindle, K., Cunningham, C. H., Gallagher, F. A., Keshari, K. R., Kjaer, A., Laustsen, C., Mankoff, D. A., Merritt, M. E., Nelson, S. J., Pauly, J. M., Lee, P., Ronen, S., Tyler, D. J., Rajan, S. S., Spielman, D. M., Wald, L., Zhang, X., Malloy, C. R., & Rizi, R. (2019). Hyperpolarized (13)C MRI: Path to clinical translation in oncology. Neoplasia., 21, 1–16.

    PubMed  Google Scholar 

  60. Rider, O. J., & Tyler, D. J. (2013). Clinical implications of cardiac hyperpolarized magnetic resonance imaging. J Cardiovasc Magn Reson, 15, 93.

    PubMed  PubMed Central  Google Scholar 

  61. Malloy, C. R., Merritt, M. E., & Sherry, A. D. (2011). Could 13C MRI assist clinical decision-making for patients with heart disease? NMR Biomed, 24, 973–979.

    PubMed  PubMed Central  Google Scholar 

  62. Schroeder, M. A., Lau, A. Z., Chen, A. P., Gu, Y., Nagendran, J., Barry, J., Hu, X., Dyck, J. R., Tyler, D. J., Clarke, K., Connelly, K. A., Wright, G. A., & Cunningham, C. H. (2013). Hyperpolarized (13)C magnetic resonance reveals early- and late-onset changes to in vivo pyruvate metabolism in the failing heart. Eur J Heart Fail, 15, 130–140.

    CAS  PubMed  Google Scholar 

  63. Cunningham, C. H., Lau, J. Y., Chen, A. P., Geraghty, B. J., Perks, W. J., Roifman, I., Wright, G. A., & Connelly, K. A. (2016). Hyperpolarized 13C metabolic MRI of the human heart: initial experience. Circ Res, 119, 1177–1182.

    CAS  PubMed  PubMed Central  Google Scholar 

  64. Ball, D. R., Rowlands, B., Dodd, M. S., Le Page, L., Ball, V., Carr, C. A., Clarke, K., & Tyler, D. J. (2014). Hyperpolarized butyrate: a metabolic probe of short chain fatty acid metabolism in the heart. Magn Reson Med, 71, 1663–1669.

    CAS  PubMed  Google Scholar 

  65. Miller, J. J., Ball, D. R., Lau, A. Z., & Tyler, D. J. (2018). Hyperpolarized ketone body metabolism in the rat heart. NMR Biomed, 31, e3912.

    PubMed  PubMed Central  Google Scholar 

  66. Flori, A., Liserani, M., Frijia, F., Giovannetti, G., Lionetti, V., Casieri, V., Positano, V., Aquaro, G. D., Recchia, F. A., Santarelli, M. F., Landini, L., Ardenkjaer-Larsen, J. H., & Menichetti, L. (2015). Real-time cardiac metabolism assessed with hyperpolarized [1-(13) C]acetate in a large-animal model. Contrast Media Mol Imaging, 10, 194–202.

    CAS  PubMed  Google Scholar 

  67. Bastiaansen, J. A., Merritt, M. E., & Comment, A. (2016). Measuring changes in substrate utilization in the myocardium in response to fasting using hyperpolarized [1-(13)C]butyrate and [1-(13)C]pyruvate. Sci Rep, 6, 25573.

    CAS  PubMed  PubMed Central  Google Scholar 

  68. Boutagy, N. E., Wu, J., Cai, Z., Zhang, W., Booth, C. J., Kyriakides, T. C., Pfau, D., Mulnix, T., Liu, Z., Miller, E. J., Young, L. H., Carson, R. E., Huang, Y., Liu, C., & Sinusas, A. J. (2018). In vivo reactive oxygen species detection with a novel positron emission tomography tracer, (18)F-DHMT, allows for early detection of anthracycline-induced cardiotoxicity in rodents. JACC Basic Transl Sci, 3, 378–390.

    PubMed  PubMed Central  Google Scholar 

  69. Keshari, K. R., Kurhanewicz, J., Bok, R., Larson, P. E., Vigneron, D. B., & Wilson, D. M. (2011). Hyperpolarized 13C dehydroascorbate as an endogenous redox sensor for in vivo metabolic imaging. Proc Natl Acad Sci U S A, 108, 18606–18611.

    CAS  PubMed  PubMed Central  Google Scholar 

  70. Lippert, A. R., Keshari, K. R., Kurhanewicz, J., & Chang, C. J. (2011). A hydrogen peroxide-responsive hyperpolarized 13C MRI contrast agent. J Am Chem Soc, 133, 3776–3779.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. Qin, H., Carroll, V. N., Sriram, R., Villanueva-Meyer, J. E., von Morze, C., Wang, Z. J., Mutch, C. A., Keshari, K. R., Flavell, R. R., Kurhanewicz, J., & Wilson, D. M. (2018). Imaging glutathione depletion in the rat brain using ascorbate-derived hyperpolarized MR and PET probes. Sci Rep, 8, 7928.

    PubMed  PubMed Central  Google Scholar 

  72. Moe, G. W., & Marin-Garcia, J. (2016). Role of cell death in the progression of heart failure. Heart Fail Rev, 21, 157–167.

    PubMed  Google Scholar 

  73. Zeng, W., Wang, X., Xu, P., Liu, G., Eden, H. S., & Chen, X. (2015). Molecular imaging of apoptosis: from micro to macro. Theranostics, 5, 559–582.

    CAS  PubMed  PubMed Central  Google Scholar 

  74. Wang, X., Feng, H., Zhao, S., Xu, J., Wu, X., Cui, J., Zhang, Y., Qin, Y., Liu, Z., Gao, T., Gao, Y., & Zeng, W. (2017). SPECT and PET radiopharmaceuticals for molecular imaging of apoptosis: from bench to clinic. Oncotarget., 8, 20476–20495.

    PubMed  PubMed Central  Google Scholar 

  75. Zhao, Y., Watanabe, A., Zhao, S., Kobayashi, T., Fukao, K., Tanaka, Y., Nakano, T., Yoshida, T., Takemoto, H., Tamaki, N., & Kuge, Y. (2014). Suppressive effects of irbesartan on inflammation and apoptosis in atherosclerotic plaques of apoE-/- mice: molecular imaging with 14C-FDG and 99mTc-annexin A5. PLoS One, 9, e89338.

    PubMed  PubMed Central  Google Scholar 

  76. Benali, K., Louedec, L., Azzouna, R. B., Merceron, O., Nassar, P., Al Shoukr, F., Petiet, A., Barbato, D., Michel, J. B., Sarda-Mantel, L., Le Guludec, D., & Rouzet, F. (2014). Preclinical validation of 99mTc-annexin A5-128 in experimental autoimmune myocarditis and infective endocarditis: comparison with 99mTc-HYNIC-annexin A5. Mol Imaging, 13.

  77. Wakabayashi, H., Taki, J., Inaki, A., Shiba, K., Matsunari, I., & Kinuya, S. (2015). Correlation between apoptosis and left ventricular remodeling in subacute phase of myocardial ischemia and reperfusion. EJNMMI Res, 5, 72.

    PubMed  PubMed Central  Google Scholar 

  78. Gabrielson, K. L., Mok, G. S., Nimmagadda, S., Bedja, D., Pin, S., Tsao, A., Wang, Y., Sooryakumar, D., Yu, S. J., Pomper, M. G., & Tsui, B. M. (2008). Detection of dose response in chronic doxorubicin-mediated cell death with cardiac technetium 99 m annexin V single-photon emission computed tomography. Mol Imaging, 7, 132–138.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Belhocine, T. Z., Blankenberg, F. G., Kartachova, M. S., Stitt, L. W., Vanderheyden, J. L., Hoebers, F. J., & Van de Wiele, C. (2015). (99 m)Tc-Annexin A5 quantification of apoptotic tumor response: a systematic review and meta-analysis of clinical imaging trials. Eur J Nucl Med Mol Imaging, 42, 2083–2097.

    CAS  PubMed  Google Scholar 

  80. Su, H., Chen, G., Gangadharmath, U., Gomez, L. F., Liang, Q., Mu, F., Mocharla, V. P., Szardenings, A. K., Walsh, J. C., Xia, C. F., Yu, C., & Kolb, H. C. (2013). Evaluation of [(18)F]-CP18 as a PET imaging tracer for apoptosis. Mol Imaging Biol, 15, 739–747.

    PubMed  Google Scholar 

  81. Su, H., Gorodny, N., Gomez, L. F., Gangadharmath, U., Mu, F., Chen, G., Walsh, J. C., Szardenings, K., Kolb, H. C., & Tamarappoo, B. (2015). Noninvasive molecular imaging of apoptosis in a mouse model of anthracycline-induced cardiotoxicity. Circ Cardiovasc Imaging, 8, e001952.

    PubMed  PubMed Central  Google Scholar 

Download references

Funding

This study was funded by Cancer Prevention Research Institute of Texas (CPRIT, RP180404 to VGZ).

Author information

Affiliations

  1. Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX, USA

    Dan Tong & Vlad G. Zaha

  2. Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, USA

    Vlad G. Zaha

  3. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, USA

    Vlad G. Zaha

Authors
  1. Dan Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vlad G. Zaha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vlad G. Zaha.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Associate Editor Ana Barac oversaw the review of this article

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tong, D., Zaha, V.G. Metabolic Imaging in Cardio-oncology. J. of Cardiovasc. Trans. Res. 13, 357–366 (2020). https://doi.org/10.1007/s12265-019-09927-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12265-019-09927-9

Keywords

  • Cardio-toxicity
  • Cancer
  • Chemotherapy
  • Metabolism